Weight-loss drugs like semaglutide, found in Wegovy and Ozempic, have shown great promise in helping people manage obesity.
These drugs belong to a class called GLP-1 receptor agonists (GLP-1 RAs), originally developed to treat type-2 diabetes.
They have gained widespread attention for their ability to “turn off” hunger, making them seem like a simple solution to the complex and chronic condition of obesity.
However, experts caution that these drugs are not a cure-all.
In an editorial published in Nutrition Bulletin, a group of obesity management professionals emphasized the importance of a comprehensive, multidisciplinary approach to weight management.
This approach should include psychological, surgical, and dietary support to ensure that patients can safely and effectively achieve their health goals.
Dr. Adrian Brown, a dietitian and lead author from UCL Division of Medicine, pointed out that while GLP-1 RAs are powerful tools for helping patients lose weight, they must be used as part of a broader strategy.
He noted that while these drugs can reduce hunger and make people feel full, they should not be viewed as a quick fix. There are still many unknowns about how best to use them in clinical practice, especially over the long term.
A comprehensive weight management plan typically involves lifestyle changes, behavioral therapy, and psychological support. This helps individuals understand their relationship with food and make healthier choices.
In some cases, bariatric surgery may be recommended, which involves making the stomach smaller to reduce food intake. However, even with surgery, a multidisciplinary team is needed to support the patient in maintaining a balanced diet and avoiding complications.
Dr. Brown also warned of potential risks associated with GLP-1 RAs. People using these drugs may eat significantly less, which can lead to nutritional deficiencies, especially in protein and essential vitamins and minerals.
There is also a concern about the loss of muscle mass, as seen in some clinical trials where participants lost a significant amount of lean tissue along with fat. The long-term effects of this on physical function are still unclear.
From a psychological perspective, Dr. Emma Shuttlewood, a clinical psychologist and co-author from University Hospitals Coventry and Warwickshire NHS Trust, highlighted that the emotional impact of using GLP-1 RAs is not well understood.
People with obesity often turn to food for comfort or pleasure, and if this source of reward is removed, they may seek other unhealthy outlets, like alcohol or overspending. There is also a risk of depression and other mental health issues if the brain’s reward centers are affected.
In conclusion, while GLP-1 RAs have the potential to revolutionize obesity treatment, they should be used carefully and as part of a broader care plan.
Dr. Brown emphasized the need for healthcare providers to work together to create a safe and sustainable approach that addresses all aspects of a patient’s well-being, ensuring that they can achieve their health goals without unintended consequences.
If you care about weight loss, please read studies about the right diet for weight loss in type 2 diabetes, and is it possible to lose weight without diet and exercise.
For more health information, please see recent studies about ginger’s journey in weight management ,and green tea: a cup of weight loss.
